P38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases

Nature Reviews Drug Discovery

Volumn 2, Issue 9, 2003, Pages 717-726

  Kumar, Sanjay ^a   Boehm, Jeffrey ^a   Lee, John C ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 2 (4 FLUOROPHENYL) 5 (4 METHYLSULFINYLPHENYL) 3 (4 PYRIDYL)PYRROLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; BENZOPHENONE DERIVATIVE; DIAMIDE; DORAMAPIMOD; ETANERCEPT; IMIDAZOLE DERIVATIVE; INDOLEAMINE; INFLIXIMAB; KETONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NAPHTHALENE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINONE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SB 242235; SCIO 469; SIGNAL PEPTIDE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; DRUG TOLERABILITY; ENZYME ACTIVATION; HUMAN; INFLAMMATION; LIVER DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRESS; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; INFLAMMATION; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 0142026209     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1177     Document Type: Review

References (75)

1. Pearson, G. et al. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr. Rev. 22, 153-183 (2001).
2. Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746 (1994).
3. Han, J., Lee, J. D., Bibbs, L. & Ulevitch, R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808-811 (1994).
4. Jiang, Y. et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38β). J. Biol. Chem. 271, 17920-17926 (1996).
5. Kumar, S. et al. Novel homologues of CSBP/p38 MAP kinase-activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem. Biophys. Res. Commun. 235, 533-538 (1997).
6. Wang, Y. B. et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem. 273, 2161-2168 (1998).
7. Li, Z., Jiang, Y., Ulevitch, R. J. & Han, J. The primary structure of p38γ. a new member of p38 group of MAP kinases. Biochem. Biophys. Res. Commun. 228, 334-340 (1996).
8. Mertens, S., Craxton, M. & Goedert, M. SAP kinase-3, a new member of the family of mammalian stress-activated protein kinases. FEBS Lett. 383, 273-276 (1996).
9. Cuenda, A., Cohen, P., Buee-Scherrer, V. & Goedert, M. Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J. 16, 295-305 (1997).
10. Court, N. W., dos Remedios, C. G., Cordell, J. & Bogoyevitch, M. A. Cardiac expression and subcellular localization of the p38 mitogen-activated protein kinase member, stress-activated protein kinase-3 (SAPK3). J. Mol. Cell. Cardiol. 34, 413-426 (2002).
11. Adams, J. L., Badger, A. M., Kumar, S. & Lee, J. C. p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. Prog. Med. Chem. 38, 1-60 (2001).
12. Kyriakis, J. M. & Avruch, J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81, 807-869 (2001).
13. Ge, B. X. et al. MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorylation of p38α. Science 295, 1291-1294 (2002).
14. Masuda, K., Shima, H., Watanabe, M. & Kikuchi, K. MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein. J. Biol. Chem. 276, 39002-39011 (2001).
15. Tanoue, T., Yamamoto, T., Maeda, R. & Nishida, E. A novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38α and β MAPKs. J. Biol. Chem. 276, 26629-26639 (2001).
16. Theodosiou, A., Smith, A., Gillieron, C., Arkinstall, S. & Ashworth, A. MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene 18, 6981-6988 (1999).
17. Allen, M. et al. Deficiency of the stress kinase p38α results in embryonic lethality: Characterization of the kinase dependence of stress response of enzyme-deficient embryonic stem cells. J. Exp. Med. 191, 859-869 (2000).
18. Kotlyarov, A. et al. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nature Cell Biol. 1, 94-97 (1999).
19. Caput, D. et al. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl Acad. Sci. USA 83, 1670-1674 (1986).
20. Shaw, G. & Kamen, R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46, 659-667 (1986).
21. Winzen, R. et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 18, 4969-4980 (1999).
22. Ming, X. F., Stoecklin, G., Lu, M., Looser, R. & Moroni, C. Parallel and independent regulation of interleukin-3 mRNA turnover by phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase. Mol. Cell. Biol. 21, 5778-5789 (2001).
23. Neininger, A. et al. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J. Biol. Chem. 277, 3065-3068 (2002).
24. Frevel, M. A. E. et al. p38 mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol. Cell. Biol. 23, 425-436 (2003).
25. Lantos, I. et al. Antiinflammatory activity of 5,6-diaryl-2,3-dihydroimidazo[2,1-b]thiazoles. Isomeric 4-pyridyl and 4-substituted phenyl derivatives. J. Med. Chem. 27, 72-75 (1984).
26. Lee, J. C., Griswold, D. E., Votta, B. & Hanna, N. Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002. Int. J. Immunopharmacol. 10, 835-843 (1988).
27. Lee, J. C. et al. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann. NY Acad. Sci. 696, 149-170 (1993).
28. Lee, J. C., Kassis, S., Kumar, S., Badger, A. & Adams, J. L. p38 mitogen-activated protein kinase inhibitors. Mechanism and therapeutic potentials. Pharmacol. Ther. 82, 389-397 (1999).
29. Gallagher, T. F. et al. 2,4,5-Triarylimidazole inhibitors of IL-1 biosynthesis. Bioorg. Med. Chem. Lett. 5, 1171-1176 (1995).
30. Gallagher, T. et al. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. 5, 49-64 (1997).
31. Adams, J. L. et al. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. 8, 3111-3116 (1998).
32. Boehm, J. C. et al. 1-substituted 4-aryl-5-pyridinyl-imidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Chem. 39, 3929-3937 (1996).
33. Adams, J. L. et al. Pyrimidinylimidazole inhibitors of p38: Cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg. Med. Chem. Lett. 11, 2867-2870 (2001).
34. Liverton, N. J. et al. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 42, 2180-2190 (1999).
35. Boehm, J. C. & Adams, J. L. New inhibitors of p38 kinase. Expert Opin. Ther. Patents 10, 25-37 (2000).
36. Jackson, P. F. & Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 2, 1011-1020 (2002).
37. Cirillo, P. F., Pargellis, C. & Regan, J. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 2, 1021-1035 (2002).
38. Wilson, K. P. et al. Crystal structure of p38 mitogen-activated protein kinase. J. Biol. Chem. 271, 27696-27700 (1996).
39. Wang, Z. et al. The structure of mitogen-activated protein kinase p38 at 2.1 Å resolution. Proc. Natl Acad. Sci. USA 94, 2327-2332 (1997).
40. Wang, Z. L. et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 6, 1117-1128 (1998).
41. Wilson, K. P. et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4, 423-431 (1997).
42. Tong, L. et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Struct. Biol. 4, 311-316 (1997).
43. Gum, R. J. et al. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem. 273, 15605-15610 (1998).
44. Fox, T. et al. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci. 7, 2249-2255 (1998).
45. Eyers, P. A., Craxton, M., Morrice, N., Cohen, P. & Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. 5, 321-328 (1998).
46. Pargellis, C. et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Struct. Biol. 9, 268-272 (2002).
47. Regan, J. et al. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J. Med. Chem. 45, 2994-3008 (2002).
48. Badger, A. M. et al. Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthr. Cartil. 8, 434-443 (2000).
49. Guan, Z. H., Buckman, S. Y., Pentland, A. P., Templeton, D. J. & Morrison, A. R. Induction of cyclooxygenase-2 by the activated MEKK1-/SEK1/MKK4-/p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 273, 12901-12908 (1998).
50. Saccani, S., Pantano, S. & Natoli, G. p38-dependent marking of inflammatory genes for increased NF-κB recruitment. Nature Immunol. 3, 69-75 (2002).
51. Bendele, A. M. et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. 43, 2648-2659 (2000).
52. Kalden, J. R. How do the biologics fit into the current DMARD armamentarium? J. Rheumatol. 28, 27-35 (2001).
53. Smolen, J. S. & Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nature Rev. Drug Discov. 2, 473-488 (2003).
54. Badger, A. M. et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Therap. 279, 1453-1461 (1996).
55. Ma, X. L. et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 99, 1685-1691 (1999).
56. Wadsworth, S. A. et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther. 291, 680-687 (1999).
57. Badger, A. M. et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 43, 175-183 (2000).
58. Revesz, L. et al. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 10, 1261-1264 (2000).
59. McLay, I. M. et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg. Med. Chem. 9, 537-554 (2001).
60. McKenna, J. M. et al. An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors. J. Med. Chem. 45, 2173-2184 (2002).
61. Behr, T. M. et al. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104, 1292-1298 (2001).
62. Hull, M., Lieb, K. & Fiebich, B. L. Pathways of inflammatory activation in Alzheimer's disease: Potential targets for disease modifying drugs. Curr. Med. Chem. 9, 83-88 (2002).
63. Kawashima, Y. et al. FR167653 attenuates ischemia and reperfusion injury of the rat lung with suppressing p38 mitogen-activated protein kinase. J. Heart Lung Transplant. 20, 568-574 (2001).
64. Kobayashi, M., Takeyoshi, I., Yoshinari, D., Matsumoto, K. & Morishita, Y. P38 mitogen-activated protein kinase inhibition attenuates ischemia-reperfusion injury of the rat liver. Surgery 131, 344-349 (2002).
65. Ju, H. S. et al. Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury. J. Pharmacol. Exp. Ther. 301, 15-20 (2002).
66. Waetzig, G. H., Seegert, D., Rosenstiel, P., Nikolaus, S. & Schreiber, S. p38 mitogen-activated protein kinase is activated and linked to TNF-α signaling in inflammatory bowel disease. J. Immunol. 168, 5342-5351 (2002).
67. Fullerton, T. et al. Suppression of ex vivo cytokine production by SB-242235, a selective inhibitor of p38 MAP kinase. 101st Ann. Meet. Am. Soc. Clin. Pharmacol. 67, 114 (2000).
68. Fijen, J. W. et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. 124, 16-20 (2001).
69. Weisman, M. et al. Double-blind, placebo-controlled trial of VX-745, an oral p38 mitogen activated protein kinase inhibitor, in patients with rheumatoid arthritis (RA). Ann. European Congress Rheumatol. A10018 (2002).
70. Wood, C. C., Yong, C. L., Madwed, J. B. & Gupta, A. Pharmacokinetics and pharmacodynamics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered once daily for 7 days. 58th Ann. Meet. Am. Acad. Allergy, Asthma Immunol. 109, S321 A993 (2002).
71. Gupta, A. et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of an oral p38 MAP kinase inhibitor (BIRB 796 BS) in healthy human males, a placebo controlled, randomized study, double blinded at each dose level. Ann. Meet. Am. Acad. Allergy, Asthma Immunol. 109, S67 A158 (2002).
72. Polmar, S. H. et al. Safety and pharmacokinetics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered twice daily for 14 days to healthy volunteers. 58th Ann. Meet. Am. Acad. Allergy, Asthma Immunol. 109, S66 A167 (2002).
73. Goldstein, D. M. The discovery and development of selective inhibitors of p38 MAP kinase from distinct chemical classes. J. Inflamm. Res. 51, S114 (2002).
74. Fearns, C. et al. Coordinate activation of endogenous p38 α, β, γ, and δ by inflammatory stimuli. J. Leukoc. Biol. 67, 705-711 (2000)
75. Barone, F. C. et al. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J. Pharmacol. Exp. Ther. 296, 312-321 (2001).